Home - Cingulate Inc
Cingulate is a clinical stage biopharmaceutical company focused on the development of innovative new product candidates for the treatments of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety …
Cingulate Inc. Reports Third Quarter 2025 Financial Results and ...
Nov 13, 2025 · “Cingulate has made meaningful progress this quarter toward key value-creating milestones,” said Jay Roberts, Executive Chairman of Cingulate.
Stock Quote & Chart - Cingulate Inc
Cingulate Secures Exclusive Manufacturing Partnership with Bend Bio Sciences to Support Future Commercialization of Next Generation ADHD Treatment Cingulate Inc. Reports Second Quarter …
Investors - Cingulate Inc
Cingulate is a clinical stage biopharmaceutical company focused on the development of innovative new product candidates for the treatments of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety …
Press Releases - Cingulate Inc
Nov 10, 2025 · Regulatory filing marks significant milestone for medication designed to provide once-daily, entire active-day symptom control in ADHD patients KANSAS CITY, Kan., Aug. 06, 2025 …
FDA Accepts Cingulate’s New Drug Application for CTx-1301 in …
Cingulate’s lead candidate, CTx-1301, is in late-stage development for ADHD, with additional candidates in anxiety and other neuropsychiatric indications. Cingulate is headquartered in Kansas City, Kansas.
Cingulate Receives $4.3M Waiver from FDA Ahead of Imminent Filing …
Jul 29, 2025 · With an initial focus on the treatment of ADHD, Cingulate is identifying and evaluating additional therapeutic areas where PTR technology may be employed to develop future product …
Cingulate Initiates Final Study for Lead ADHD Asset CTx-1301 ...
Sep 12, 2024 · With an initial focus on the treatment of ADHD, Cingulate is identifying and evaluating additional therapeutic areas where PTR technology may be employed to develop future product …
Pipeline - Cingulate Inc
Cingulate currently has three (3) product candidates, CTx-1301 (dexmethylphenidate), CTx-1302 (dextroamphetamine) and CTx-2103 (anxiety) in the pipeline. All three therapies utilize Cingulate’s …
Efficacy Results Announced from Cingulate’s Phase 3 Pediatric Study of ...
May 20, 2025 · Last month Cingulate announced positive top-line results of a high dose (50-mg) food effect study for CTx-1301, with the primary endpoints establishing that it can be taken with or without …